|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
ocn904046276 |
| 003 |
OCoLC |
| 005 |
20240909213021.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
150226s2015 gw ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d DG1
|d E7B
|d OCLCF
|d CDX
|d COO
|d YDXCP
|d IDEBK
|d DEBSZ
|d EBLCP
|d DG1
|d K6U
|d COCUF
|d DG1
|d OCLCQ
|d CCO
|d LIP
|d PIFFA
|d FVL
|d ZCU
|d OCLCQ
|d MERUC
|d U3W
|d OCLCQ
|d STF
|d ICG
|d VT2
|d OCLCO
|d OCLCQ
|d UWO
|d OCLCO
|d WYU
|d CUY
|d OCLCO
|d OCLCA
|d MERER
|d TKN
|d OCLCQ
|d DKC
|d OCLCQ
|d UKAHL
|d OCLCQ
|d OCLCA
|d TUHNV
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|d SXB
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBB515158
|2 bnb
|
| 019 |
|
|
|a 961646872
|a 962625293
|a 989360268
|a 1055362438
|a 1066619254
|a 1081204161
|a 1228554571
|a 1244444040
|a 1249243504
|
| 020 |
|
|
|a 9783527680658
|q (electronic bk.)
|
| 020 |
|
|
|a 3527680659
|q (electronic bk.)
|
| 020 |
|
|
|a 9783527680665
|q (electronic bk.)
|
| 020 |
|
|
|a 3527680667
|q (electronic bk.)
|
| 020 |
|
|
|a 3527337199
|
| 020 |
|
|
|a 9783527337194
|
| 020 |
|
|
|a 9783527680672
|q (Epub)
|
| 020 |
|
|
|a 3527680675
|q (Epub)
|
| 020 |
|
|
|a 9783527680689
|q (mobi)
|
| 020 |
|
|
|a 3527680683
|q (mobi)
|
| 020 |
|
|
|z 9783527337194
|
| 035 |
|
|
|a (OCoLC)904046276
|z (OCoLC)961646872
|z (OCoLC)962625293
|z (OCoLC)989360268
|z (OCoLC)1055362438
|z (OCoLC)1066619254
|z (OCoLC)1081204161
|z (OCoLC)1228554571
|z (OCoLC)1244444040
|z (OCoLC)1249243504
|
| 050 |
|
4 |
|a QH438.4.B55
|
| 072 |
|
7 |
|a SCI
|x 007000
|2 bisacsh
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Biomarker validation :
|b technological, clinical and commercial aspects /
|c edited by Harald Seitz and Sarah Schumacher.
|
| 264 |
|
1 |
|a Weinheim, Germany :
|b Wiley-VCH,
|c 2015.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Vendor-supplied metadata.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Related Titles; Title Page; Copyright; Table of Contents; List of Contributors; Chapter 1: Biomarkers -- Past and Future; 1.1 Introduction; 1.2 Definitions of Biomarkers; 1.3 Biomarkers in the Past; 1.4 Novel Molecules and Structural Classes of Biomarkers by New Technologies; 1.5 Biomarkers in Drug Research; 1.7 Summary and Outlook; References; Chapter 2: Quantitative Proteomics Techniques in Biomarker Discovery; 2.1 Introduction; 2.2 2D-Difference Gel Electrophoresis; 2.3 Mass Spectrometry-Based Proteomics; 2.4 MALDI Mass Spectrometry Imaging; 2.5 Conclusion; References.
|
| 505 |
8 |
|
|a Chapter 3: Biomarker Qualification: A Company Point of View3.1 Introduction; 3.2 Biomarker Uses; 3.3 Biomarker Types; 3.4 Validation vs. Qualification; 3.5 Strategic Choices in Business Models; 3.6 Validation of Analytical Methods; 3.7 Clinical Qualification of Candidate Biomarkers; 3.8 Biomarker Qualification in the 'omics Era; 3.9 An Example of a Biomarker Provider; 3.10 Conclusion; References; Chapter 4: Biomarker Discovery and Medical Diagnostic Imaging; 4.1 Introduction; 4.2 Factors to Consider in Biomarker Selection for Imaging.
|
| 505 |
8 |
|
|a 4.3 Defining the Insertion Point of the Assay and Its Business Case4.4 Practical In Vitro Methods Used to Identify Biomarkers; 4.5 Preclinical Models; 4.6 Preclinical Analysis Techniques; 4.7 Translational Considerations and Restrictions; 4.8 Other Uses of Preclinical Models; 4.9 Nuclear Imaging Infrastructure; 4.10 Image Processing; 4.11 Concluding Remarks; References; Chapter 5: Breath: An Often Overlooked Medium in Biomarker Discovery; 5.1 Introduction; 5.2 Breath Analysis Studies: Targets, Techniques, and Approaches; 5.3 Biomarker Confounders; 5.4 Biomarkers in Breath.
|
| 505 |
8 |
|
|a 5.5 Outlook for Breath AnalysisAcknowledgments; References; Chapter 6: HTA in Personalized Medicine Technologies; 6.1 Introduction; 6.2 Health Technology Assessment (HTA); 6.3 Validation and Evaluation of Biomarker Tests; 6.4 Health Technology Assessment of Personalized Medicine Technologies; 6.5 Concluding Remarks; References; Chapter 7: Bone Remodeling Biomarkers: New Actors on the Old Cardiovascular Stage; 7.1 Introduction; 7.2 Cardiovascular Disease and Osteoporosis: Common Risk Factors and Common Pathophysiological Mechanisms; 7.3 Biomarkers of Bone Health in CVD; 7.4 Conclusion.
|
| 520 |
|
|
|a Built on a decade of experience with novel molecular diagnostics, this practice-oriented guide shows how to cope with validation issues during all stages of biomarker development, from the first clinical studies to the eventual commercialization of a new diagnostic test.
|
| 650 |
|
0 |
|a Biochemical markers.
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Biochemistry.
|2 bisacsh
|
| 650 |
|
7 |
|a Biochemical markers
|2 fast
|
| 700 |
1 |
|
|a Seitz, Harald,
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjDq7KdhGPvTTkGRBvpbgq
|
| 700 |
1 |
|
|a Schumacher, Sarah,
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjHQ9TfcKcM6MJbx3cFKr3
|
| 758 |
|
|
|i has work:
|a Biomarker validation (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFMy9tKmxgtgYjBjcWHBfq
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|z 9783527680658
|w (OCoLC)904046276
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=1964220
|y Click for online access
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|